HAVCR1 in cancer: A systematic review of its dual-faceted role as a biomarker and therapeutic target

IF 1 Q4 GENETICS & HEREDITY

Gene Reports Pub Date : 2025-02-25 DOI:10.1016/j.genrep.2025.102178

Amirali Soltaninegar , Fatemeh Sadat Jalilzadeh Ghahi , Sepideh Hosseini , Najaf Allahyari Fard

{"title":"HAVCR1 in cancer: A systematic review of its dual-faceted role as a biomarker and therapeutic target","authors":"Amirali Soltaninegar , Fatemeh Sadat Jalilzadeh Ghahi , Sepideh Hosseini , Najaf Allahyari Fard","doi":"10.1016/j.genrep.2025.102178","DOIUrl":null,"url":null,"abstract":"<div><div>Hepatitis A virus cellular receptor 1 (HAVCR1), also known as KIM-1 in kidney diseases and TIM-1 or CD365 in immunology, is a class 1 integral membrane glycoprotein member that plays a pivotal role in cancer progression, diagnosis, and potential treatment. This review study aims to explore the various aspects of the HAVCR1 protein, focusing on its role as a potential biomarker and therapeutic target in different types of cancers and analyze the correlation of HAVCR1 with prognosis, underlying molecular mechanisms, and its clinical potential in cancer diagnosis and treatment. In cancers such as RCC, ESCA, LIHC, PAAD, LUAD, and OV, HAVCR1 is associated with poor prognosis, whereas in others like COAD, RB, SKCM, and BLCA, it correlates with improved outcomes. HAVCR1 contributes to cancer progression through the MAPK/ERK and PI3K/AKT pathways, which regulate immune suppression, cell growth, survival, migration, and angiogenesis. Its expression level, shedding, and localization significantly influence its role in cancer in the plasma or internal membranes. The release of the HAVCR1 ectodomain during shedding and its detectability in urine, blood, and cerebrospinal fluid highlight its potential as a biomarker for diagnosing specific cancers. Furthermore, HAVCR1 represents a promising target for therapeutic interventions in oncology.</div></div>","PeriodicalId":12673,"journal":{"name":"Gene Reports","volume":"39 ","pages":"Article 102178"},"PeriodicalIF":1.0000,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gene Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452014425000512","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 0

Abstract

Hepatitis A virus cellular receptor 1 (HAVCR1), also known as KIM-1 in kidney diseases and TIM-1 or CD365 in immunology, is a class 1 integral membrane glycoprotein member that plays a pivotal role in cancer progression, diagnosis, and potential treatment. This review study aims to explore the various aspects of the HAVCR1 protein, focusing on its role as a potential biomarker and therapeutic target in different types of cancers and analyze the correlation of HAVCR1 with prognosis, underlying molecular mechanisms, and its clinical potential in cancer diagnosis and treatment. In cancers such as RCC, ESCA, LIHC, PAAD, LUAD, and OV, HAVCR1 is associated with poor prognosis, whereas in others like COAD, RB, SKCM, and BLCA, it correlates with improved outcomes. HAVCR1 contributes to cancer progression through the MAPK/ERK and PI3K/AKT pathways, which regulate immune suppression, cell growth, survival, migration, and angiogenesis. Its expression level, shedding, and localization significantly influence its role in cancer in the plasma or internal membranes. The release of the HAVCR1 ectodomain during shedding and its detectability in urine, blood, and cerebrospinal fluid highlight its potential as a biomarker for diagnosing specific cancers. Furthermore, HAVCR1 represents a promising target for therapeutic interventions in oncology.

查看原文本刊更多论文

HAVCR1在癌症中的作用：其作为生物标志物和治疗靶点的双重作用的系统回顾

甲型肝炎病毒细胞受体1 (HAVCR1)，在肾脏疾病中称为KIM-1，在免疫学中称为TIM-1或CD365，是1类完整膜糖蛋白成员，在癌症进展、诊断和潜在治疗中起关键作用。本综述旨在探讨HAVCR1蛋白的各个方面，重点关注其在不同类型癌症中作为潜在生物标志物和治疗靶点的作用，并分析HAVCR1与预后的相关性、潜在的分子机制及其在癌症诊断和治疗中的临床潜力。在RCC、ESCA、LIHC、PAAD、LUAD和OV等癌症中，HAVCR1与预后不良相关，而在COAD、RB、SKCM和BLCA等其他癌症中，HAVCR1与预后改善相关。HAVCR1通过MAPK/ERK和PI3K/AKT通路参与癌症进展，调控免疫抑制、细胞生长、存活、迁移和血管生成。其表达水平、脱落和定位显著影响其在血浆或细胞膜中的癌症作用。脱落过程中HAVCR1外结构域的释放及其在尿液、血液和脑脊液中的可检测性突出了其作为诊断特定癌症的生物标志物的潜力。此外，HAVCR1代表了肿瘤治疗干预的一个有希望的靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gene Reports Biochemistry, Genetics and Molecular Biology-Genetics

CiteScore

3.30

自引率

7.70%

发文量

246

审稿时长

49 days

期刊介绍： Gene Reports publishes papers that focus on the regulation, expression, function and evolution of genes in all biological contexts, including all prokaryotic and eukaryotic organisms, as well as viruses. Gene Reports strives to be a very diverse journal and topics in all fields will be considered for publication. Although not limited to the following, some general topics include: DNA Organization, Replication & Evolution -Focus on genomic DNA (chromosomal organization, comparative genomics, DNA replication, DNA repair, mobile DNA, mitochondrial DNA, chloroplast DNA). Expression & Function - Focus on functional RNAs (microRNAs, tRNAs, rRNAs, mRNA splicing, alternative polyadenylation) Regulation - Focus on processes that mediate gene-read out (epigenetics, chromatin, histone code, transcription, translation, protein degradation). Cell Signaling - Focus on mechanisms that control information flow into the nucleus to control gene expression (kinase and phosphatase pathways controlled by extra-cellular ligands, Wnt, Notch, TGFbeta/BMPs, FGFs, IGFs etc.) Profiling of gene expression and genetic variation - Focus on high throughput approaches (e.g., DeepSeq, ChIP-Seq, Affymetrix microarrays, proteomics) that define gene regulatory circuitry, molecular pathways and protein/protein networks. Genetics - Focus on development in model organisms (e.g., mouse, frog, fruit fly, worm), human genetic variation, population genetics, as well as agricultural and veterinary genetics. Molecular Pathology & Regenerative Medicine - Focus on the deregulation of molecular processes in human diseases and mechanisms supporting regeneration of tissues through pluripotent or multipotent stem cells.